Feng Xu

US Patent:

6569461, May 27, 2003

Filed:

Apr 26, 2000

Appl. No.:

09/558800

Inventors:

Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 900

US Classification:

424497, 424400, 424464, 424465, 424482, 424490

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

7009055, Mar 7, 2006

Filed:

Jul 19, 2002

Appl. No.:

10/484610

Inventors:

Feng Xu - Staten Island NY, US
Kimberly A. Savary - Rahway NJ, US
John M. Williams - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 215/16

US Classification:

546177, 546180, 568 34, 568 28

Abstract:

A dibromomethyl moiety is converted to a sulfonylmethyl moiety by treatment with a sulfinic acid salt. For example, (methyl-sulfonyl)methyl bromo-quinoline is prepared by the treatment of dibromomethyl bromo-quinoline with a sulfinic acid salt.

US Patent:

7339054, Mar 4, 2008

Filed:

Feb 6, 2004

Appl. No.:

10/544575

Inventors:

Feng Xu - Staten Island NY, US
Matthew M Bio - London, GB
Cameron Cowden - Hoddesdon, GB
Kimberly A. Petrillo - Philadelphia PA, US
J. Michael Williams - Hillsborough NJ, US
Chunhua Yang - Edison NJ, US
Marjorie See Waters - Cranbury NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 19/14
C07D 487/00

US Classification:

536 2711, 536 272, 544262

Abstract:

A process is provided for the preparation of branched-chain ribonucleosides of formula (I):.

US Patent:

7902376, Mar 8, 2011

Filed:

Jan 22, 2009

Appl. No.:

12/321533

Inventors:

Feng Xu - Staten Island NY, US
Mary M. Kim - Cheltenham PA, US
Yoshinori Kohmura - Ibaraki, JP
Tricia Sladicka - Schenectady NY, US
Jonathan D. Rosen - Iowa City IA, US
Michael J. Zacuto - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Banyu Pharmaceutical Co., Ltd. - Tokyo

International Classification:

C07D 498/04
C07D 487/04
C07D 309/10

US Classification:

548218, 548242, 5483605, 549419

Abstract:

A novel process is provided for the preparation of chiral trans-2,3-disubstituted 5-oxotetrahydropyrans of structural formula (I):.

US Patent:

8022084, Sep 20, 2011

Filed:

Jan 26, 2006

Appl. No.:

11/813796

Inventors:

Daniel J. Kumke - Rahway NJ, US
Jerry A. Murry - Rahway NJ, US
Bryon L. Simmons - Rahway NJ, US
Feng Xu - Rahway NJ, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4355
C07D 498/04

US Classification:

514302, 546116

Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

US Patent:

8193216, Jun 5, 2012

Filed:

Aug 16, 2011

Appl. No.:

13/210908

Inventors:

Daniel J. Kumke - Colts Neck NJ, US
Jerry A. Murry - Thousand Oaks CA, US
Bryon L. Simmons - Hamilton NJ, US
Feng Xu - Staten Island NY, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4355
C07D 498/04

US Classification:

514302, 546116

Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

US Patent:

20030176501, Sep 18, 2003

Filed:

Nov 13, 2002

Appl. No.:

10/293153

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US

International Classification:

C07C069/34
A61K031/225

US Classification:

514/548000, 560/146000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

US Patent:

20030211151, Nov 13, 2003

Filed:

Apr 29, 2003

Appl. No.:

10/425154

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Jose Vega - Trappe PA, US
Mandana Asgharnejad - Ambler PA, US

Assignee:

Merck & Co., Inc.

International Classification:

A61K031/225
A61K009/22
A61K009/16
A61K009/50

US Classification:

424/468000, 514/548000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.